There is increasing interest in the use of genetic approaches to provide a better understanding of the causes of Type II (non-insulin-dependent) diabetes mellitus and how it develops. These studies have shown that heterozygous mutations in the glycolytic enzyme glucokinase and the transcription factors hepatocyte nuclear factor (HNF)-1a, ±4a and 1b [1, 2] and insulin promoter factor-1 (IPF1) [3] can cause MODY (maturity onset diabetes of the young) and, in rare cases, late onset Type II diabetes [4] .
scription factors may have in the development of diabetes. This result has focused molecular genetic studies of diabetes on other transcription factors expressed in the pancreatic beta cell. The basic helixloop-helix transcription factor BETA2/NEUROD1 (gene symbol, NEUROD1) and the paired box homeodomain transcription factor PAX4 (PAX4) have an important role in islet and beta-cell development. We have examined the contribution of these transcription factors to the development of MODY and late-onset Type II (non-insulin-dependent) diabetes mellitus. Methods. Linkage studies have been done in MODY families reported to have no mutations in the five known MODY genes and in affected sibling pairs from families with late-onset Type II diabetes. Mutation screening of the coding regions of both genes was also realised by SSCP followed by sequencing in MODY patients and in probands with late-onset Type II diabetes.
Results. There was no evidence of linkage with the markers for NEUROD1 and PAX4 either with MODY or late-onset Type II diabetes. Mutation screening showed single nucleotide polymorphisms, several of which resulted in amino acid substitutions : NEUROD1, Ala45Thr; PAX4, Pro321His and Pro334Ala. These amino acid sequence variants were not associated with Type II diabetes. Conclusion/interpretation. Our results indicate that NEUROD1 and PAX4 are not a common cause of either MODY or late-onset Type II diabetes in the French Caucasian population. [Diabetologia (1999) 
42: 480±484]
Keywords MODY, late-onset Type II diabetes, transcription factors, PAX4, BETA2/NEUROD1, SSCP. a member of the basic helix-loop helix family of transcription factors which activates the insulin gene transcription [5] , exhibited a striking reduction in the number of beta cells, failed to develop mature islets and died perinatally from severe diabetes [6] . PAX4 is a member of the paired box homeodomain family. It is expressed in the early pancreas but is later restricted to beta cells. Inactivation of PAX4 results in the absence of mature insulin and somatostatin-producing cells in the pancreas and an increase of glucagon-producing alpha cells [7] .
To examine the contribution of NEUROD1 and PAX4 to the development of MODY and late-onset Type II diabetes, we did family linkage analyses using markers located in the vicinity of these genes. In addition, we screened these genes for mutations in MODY patients reported to have no mutations in the five known MODY genes (MODY X patients) and in late-onset Type II diabetic probands having possibly a primary defect in insulin secretion. A group of obese late-onset Type II diabetic probands were also screened for mutations in PAX4.
Subjects and methods
All families and patients with late-onset Type II diabetes used for the screening and association studies came from 550 French Caucasian Type II diabetic pedigrees recruited through a multimedia campaign.
Linkage studies. Linkage studies were done using markers located near NEUROD1 (D2S1391 and D2S364) and PAX4 (D7S504, D7S635). We first localized NEUROD1 within the linkage map of chromosome 2 using the Genebridge 4 Radiation Hybrid Panel (Research Genetics, Huntsville, Ala., USA) and analysed data using the computer program RHMAP3.0 from the Statistical Package for Multipoint Radiation Hybrid Mapping [8] . The gene NEUROD1 was localized between markers D2S324 (191 cM) and D2S118 (197 cM). The markers D2S1391 and D2S364 (193 cM) lie within this 6 cM interval. The PAX4 gene was localized on chromosome 7 at 133.8 cM [9] and D7S686 (132 cM) and D7S504 (133 cM) were selected as markers for PAX4.
The D2S364 and D7S504 markers were typed in 8 pedigrees suitable for linkage analysis among the 11 french MODY X families described previously [10] using automated-fluorescent based procedures. Since one marker per locus is possibly not sufficient to evaluate the role that a gene can have in a complex disease such as late-onset Type II diabetes, D2S364, D2S1391, D7S504 and D7S686 were typed in members of 149 late-onset Type II diabetes families. These families came from the group of 172 pedigrees described previously [11] from which we excluded families with bilineal transmission of diabetes. Affected status was determined by clinical and biological examinations including oral glucose tolerance testing. Two different categories of affected status based on severity of hyperglycaemia were considered. We used both conservative criteria for Type II diabetes (referred to as ªovert Type II diabetesº) as newly defined by the World Health Organization (WHO) in 1997 [12] , which yielded 395 affected people, of whom 85 % were being treated with oral hyperglycaemic agents or insulin and less stringent criteria for affected status (referred to as ªall affectedº) including overt Type II diabetes, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) according to WHO criteria 1997, which yielded 470 affected people.
Mutation screening of NEUROD1 and PAX4. The coding regions and flanking introns of NEUROD1 (exon 2 ± the first one is untranslated) and PAX4 (nine exons) genes were screened for mutations in one diabetic proband from each of the 11 MODY X pedigrees and in 58 subjects with late-onset Type II diabetes. The latter were lean (BMI £ 27 kg/m 2 ) with Type II diabetes diagnosed before 46 years of age, features which might indicate a primary defect in insulin secretion (Table 1). In addition, we screened PAX4 for mutations in 23 obese Type II diabetic probands belonging to the 23 families which contributed to the indication of linkage obtained at D7S686 (Table 1) .
We carried out PCR using primer pairs yielding fragments of a size of 156 to 338 bp: an amplicon per exon for PAX4 and four overlapping segments for the exon 2 (1068 bp) of the NEUROD1 gene. We used a SSCP (Single Strand Conformation Polymorphism) protocol based on fluorescent end-labelling primer, using an ABI Prism 377 DNA sequencer, as developed in our laboratory [13] . The gel temperature on the automated sequencer was maintained at 20°C with an external cooling system.
For each DNA variant found by SSCP, PCR products were directly sequenced on both strands using an Ampli Taq FS dRhodamine Terminator Cycle sequencing kit (PE, Applied Biosystems, Foster City, Calif., USA) and an automated sequencer (ABI 377).
Association studies. Association studies were conducted in 198 unrelated Type II diabetic patients (58 probands plus 140 subjects) and in 114 unrelated normoglycaemic spouses from the same families. The rare PAX4 Pro334Ala substitution was tested in an additional 228 Type II diabetic and 112 control subjects ( Table 1) .
The NEUROD1 Ala45Thr and PAX4 Pro321His and Pro334Ala mutations result in a loss of a MwoI (New England Biolabs, Beverly, USA) site and a gain of MaeIII (Boehringer Mannheim, Mannheim, Germany) and Cac8I (New England Biolabs) sites, respectively and, therefore, subjects were screened for these substitutions by PCR-RFLP. The DNA fragments were separated on a 2 % agarose gel and made visual by ethidium bromide staining. 
Statistics
Linkage analyses. The lod-score calculations in MODY families have been computed as previously [14] . Analyses in sibpairs with late-onset Type II diabetes were done on the overall sample and on three different subgroups comprising affected sib-pairs with an age at diagnosis of 45 years or less, or obese (BMI > 27 kg/m 2 ) or lean (BMI £ 27 kg/m 2 ) sib-pairs. Evidence for linkage was sought using three non-parametric affected sib-pair methods which were shown to display different statistical properties: the Haseman-Elston sib-pair method implemented in the computer program SIBPAL of the SAGE package [15] , the MLS (maximum LOD score) and exclusion score methods computed using the program MAPMAKER/ SIBS [16] and a third method based on the number of shared and non-shared alleles among affected sib-pairs computed from informative meioses with the program SIBPAIR of the ANALYZE package [17] . To evaluate the power of our linkage studies, we tested ascending values of recurrent sibling risk (ls) using the program MAPMAKER/SIBS [15] , under the no dominance variance hypothesis, and retained the ls for which the exclusion score was lower than ±2. Distance between adjacent markers were checked using MLINK program of the VITESSE package [18] .
Association analyses. Genotype frequencies in the Type II diabetic and control groups were compared using chi-squared ratios calculated under dominant, codominant and recessive models. We used ANOVA to test the association between each polymorphism and BMI or age at diagnosis of diabetes (we excluded the group of 58 Type II diabetic patients used for the screening as they were selected according to those clinical data).
Results

MODY.
Cumulative lod-scores showed exclusion of linkage with diabetes with the NEUROD1 (LOD score at v 0 = ±12.16) and PAX4 (±13.16) loci in eight MODY X families suitable for linkage analysis. Moreover, none of the LOD scores indicated evidence of linkage in any of the MODY pedigrees: they ranged from ±3.97 to 0.01 for D2S364 and from ±4.26 to 0.94 for D7S504.
Mutation screening of the NEUROD1 gene showed only the previously described Ala45Thr polymorphism in NEUROD1 [19] : six probands were heterozygous and three were homozygous. In the PAX4 gene, three silent mutations were identified and a heterozygous C-to-A transversion in exon 9 resulting in a proline to histidine substitution (Pro321His) being found in three patients (Table 2) .
Late-onset Type II diabetes. Distances between adjacent markers in our sample, as determined by MLINK were 3 cM between D2S1391 and D2S364 and 2 cM between D7S504 and D7S686, which is similar to the critical distance maps (see Methods), thus indicating a reliable quality of the genotyping.
We found no evidence of linkage between diabetes and the NEUROD1 D2S1391, D2S364, or the PAX4 D7S504 markers in any of the subgroups studied regardless of affection status and type of analysis done. There was also no evidence for PAX4-D7S686 linkage in the overall group but some indication for linkage with diabetes in the subgroup of 102 obese diabetic sib-pairs with excess allele sharing 0.57 ± 0.28 (mean proportion of alleles ± SD, p = 0.006) using SIBPAL; MLS = 1.97 (p = 0.002) using MAP-MAKER/SIBS; and 97.1 shared alleles/67.9 not shared alleles (p = 0.01) using SIBPAIR (Table 3) .
We screened NEUROD1 for mutations in 58 Type II diabetic probands with features consistent with a primary defect in insulin secretion ( Table 2 ). The screening showed the Ala45Thr polymorphism and a heterozygous C-to-T transition in intron 1, 32 nucleotides upstream of exon 2, in one subject. This substitution did not co-segregate with Type II diabetes in his family. Because of the indication of linkage detected at the PAX4 locus in the subgroup of obese diabetic sib-pairs, we selected one proband from each of the 23 families which contributed to the indication of linkage to screen for mutations in PAX4. In addition, we also screened the 58 lean Type II diabetic probands described above. The four variations found in the MODY probands were identified among these 81 subjects (Table 2) . We detected five additional single nucleotide substitutions in isolated patients, among them a C-to-G transversion in exon 9 resulting in a proline to alanine (Pro334Ala) missense mutation. This Pro334Ala substitution was only found in the heterozygous state in 1 of the 58 lean Type II diabetic subjects and did not co-segregate with diabetes in his family as it is inherited from the non-diabetic parent.
Association studies. No association was found between the NEUROD1-Ala45Thr, the PAX4-Pro321-His polymorphisms and either diabetes (Table 2) or BMI or age at onset of the disease (data not shown). The Pro334Ala substitution is very rare and was not found in any of the 198 Type II diabetic or 114 control subjects systematically used for an association study or in an additional 228 Type II diabetic and 112 control subjects (Table 2) .
Discussion
By linkage and screening studies, we found no evidence for NEUROD1 and PAX4 genes having a role in MODY or late-onset Type II diabetic French families. The design of our study in late-onset Type II diabetic pedigrees allowed us to reach the exclusion standard score of ±2 for both loci for a recurrent sibling risk (ls) of 1.2 to 1.4 in the whole sample and of 2 to 3.5 in the different sub-groups. Moreover, none of the missense mutations detected in the coding regions were associated with Type II diabetes when considering a risk ratio of at least 2 which confers a power in our study of more than 80 %. Thus, although we cannot exclude the presence of other mutations not detected by SSCP or located in promoters or untranslated sequences, it is improbable that a mutation in the NEUROD1 and PAX4 genes are a frequent cause of Type II diabetes. The number of subjects screened would, however, not allow us to identify any potential diabetogenic variant in any gene with a prevalence below 2 %.
Three other studies, investigating coding sequences of NEUROD1, also describe the detection of the Ala45Thr polymorphism through PCR-SSCP or direct sequencing in different nationality groups but no association was found with Type I (insulin-dependent) diabetes mellitus in the American group [19] , MODY in the Japanese group [20] or with late-onset Type II diabetes in the Danish Caucasian group [21] . c n is the total number of affected sib-pairs genotyped for a given marker.
d Estimated mean proportion and standard deviation (SD) of IBD alleles and the corresponding p value using the Haseman-Elston method.
e Maximum LOD score and the corresponding p value.
f Number of shared and non-shared IBD alleles among affected sib-pairs and the corresponding p value A recent work reported no linkage between the PAX4 locus and late-onset Type II diabetes in Ashkenazi Jews [22] . Our study, together with the reports cited above, indicates that NEUROD1 and PAX4 are not a common cause of either MODY or late-onset Type II diabetes.
